Эволюция системной лекарственной терапии диссеминированного рака эндометрия. Обзор литературы

Эволюция системной лекарственной терапии диссеминированного рака эндометрия. Обзор литературы

Автор: Даренская А. Д., Румянцев А. А., Гуторов С. Л., Тюляндина А. С.

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Обзоры и аналитика

Статья в выпуске: 2 т.13, 2023 года.

Бесплатный доступ

«Золотым стандартом» I линии лекарственной терапии диссеминированного рака эндометрия (РЭ) является комбинация «ТС» (Паклитаксел + Карбоплатин). Гормонотерапия (ГТ) в качестве терапии I линии рекомендована ограниченной группе пациенток. До недавнего времени прогноз больных диссеминированным РЭ, несмотря на проводимые стандартные методы лечения (химиотерапия (ХТ) и ГТ), оставался неутешительным. Ни один из цитостатиков, имеющихся в арсенале онкологов-химиотерапевтов, не обеспечивал долговременного контроля болезни и длительной выживаемости пациенток, получивших стандартную платиносодержащую терапию. Очевидно, что неудовлетворительные результаты лечения больных диссеминированным РЭ требовали изменения подходов к терапии и указывали на необходимость разработки более эффективных режимов лечения. Углубленное понимание механизмов канцерогенеза, появление новой молекулярной классификации РЭ и разделение лечебных подходов в зависимости от биологического потенциала опухоли привели к значительному прорыву в лечении диссеминированного РЭ. Одним из наиболее значительных прорывов следует считать открытие роли микро-сателлитной нестабильности (microsatellite instability, MSI) и нарушений в системе репарации неспаренных оснований ДНК (mismatch repair system, MMR) как предиктора высокой эффективности иммунотерапии - нового направления системной лекарственной терапии диссеминированного РЭ. Данная обзорная статья посвящена эволюции системной лекарственной терапии диссеминированного РЭ. В статье мы подробно обсуждаем результаты основных международных исследований по вопросам ГТ, ХТ I и II линий, таргетной терапии, иммунотерапии, а также иммунотаргетной терапии диссеминированного РЭ. Подробно рассматриваем такие биологические маркеры, как MSI, PD-L1, их влияние на эффективность лечения; разбираем механизм, лежащий в основе синергетического эффекта комбинации пембролизумаб + ленватиниб.

Еще

Рак эндометрия, микросателлитная нестабильность, msi, mss, пембролизумаб, ленватиниб, иммунотерапия, химиотерапия, гормонотерапия, таргетная терапия, mmr, pd-1, pd-l1

Короткий адрес: https://sciup.org/140300130

IDR: 140300130   |   DOI: 10.18027/2224-5057-2023-13-2-6

Список литературы Эволюция системной лекарственной терапии диссеминированного рака эндометрия. Обзор литературы

  • Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, A.О. Шахзадовой - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022 .- илл .- 239 с.
  • Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А. Д. Каприна, B.В. Старинского, А.О. Шахзадовой — М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, - 2022 .- илл .- 252 с.
  • Kelley R. M., Baker W. H. Progestational agents in the treatment of carcinoma of the endometrium// N. Engl.J. Med .- 1961 — Vol. 264 .- 216-222. Doi: 10.1056/NEJM196102022640503.
  • Thigpen J.T., Brady M.F., Alvarez R.D. et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999 ; 17 (6): 1736-1744. Doi: 10.1200/jc0. 1999.17.6.1736.
  • Pandya K.J., Yeap B.Y., Weiner L. M. et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: An Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 2001 ; 24 (1): 43-46. Doi: 10.1097/00000421200102000-00007.
  • Carlson J.A., Allegra J. C., Day T. G. I. et al. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia// Amer.J. Obstet. Gynecol .- 1984 ; 149 (2) .- 149-153. Doi: 10.1016/0002-9378(84)90187-x.
  • Vishnevsky A. S., Tsyrlina E.V., Sofroniy D. F. et al. Criteria of endometrial carcinoma sensitivity to hormone therapy: pathogenetic type of the disease and the tumor reaction to tamoxifen// Europ. J. Gynaecol. Oncol .- 1993 ; 14 (2) .- 139-143.
  • Kline R. C., Freedman R. S., Jones L. A. et al. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate// Cancer. Treat. Rep .- 1987 ; 71 (3) .- P. 327-328.
  • Pandya K.J., Yeap B.Y., Davis T. E. Phase II study of megestrol and megestrol+ tamoxifen in advanved endometrial carcinoma: an Eastern Cooperative Oncology Group Study. Abstract// Proc. Amer.Ass. Cancer. Res .- 1989 .- Vol. 30 .- 1037 p.
  • Fiorica J.V., Brunetto V.L., Hanjani P. et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004 ; 92 (1): 10-14. Doi: 10.1016/j.ygyno.2003.11.008.
  • Whitney C.W., Brunetto V.L., Zaino R.J. et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004 ; 92 (1): 4-9. Doi: 10.1016/j. ygyno.2003.09.018.
  • Rose P. G., Brunetto V. L., VanLe L. et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2000 ; 78 (2): 212-216. Doi: 10.1006/gyno.2000.5865.
  • Ma B.B., Oza A., Eisenhauer E. et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004 ; 14 (4): 650-658. Doi: 10.1111/j.1048-891X.2004.14419.x.
  • Asbury R. F., Brunetto V. L., Lee R. B. et al. Goserelin acetate as treatment for recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Am J Clin Oncol 2002 ; 25 (6): 557-560. Doi: 10.1097/00000421-200212000-00004.
  • Lhomm'e C., Vennin P., Callet N. et al. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation Study. Gynecol Oncol 1999 ; 75 (2): 187-193. Doi: 10.1006/gyno.1999.5538.
  • Rendina G.M., Donadio C., Fabri M. et al. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol, 1984 ; 17 (4): 285-91. Doi: 10.1016/0028-2243(84)90071-6.
  • Thigpen T., Brady M. F., Homesley H. D. et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2001 ; 19 (2): 364-367. Doi: 10.1200/JCO.2001.19.2.364.
  • McMeekin D. S., Gordon A., Fowler J. et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 2003 ; 90 (1): 64-69. Doi: 10.1016/s0090-8258(03)00203-8.
  • Covens A.L., Filiaci V., Gersell D. et al. Phase II study of fulvestrant in recurrent / metastatic endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2011 ; 120 (2): 185-188. Doi: 10.1016/j.ygyno.2010.10.015.
  • Emons G., Gunthert A., Thiel F.C. et al. Phase II study of fulvestrant 250 mg/ month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynakologische Onkologie. Gynecol Oncol 2013 ; 129 (3): 495-499. Doi: 10.1016/j.ygyno.2013.02.039.
  • Thigpen J. T., Blessing J. A., DiSaia P. J. et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol, 1994. 12 (7): 1408-1414. Doi: 10.1200/JCO.1994.12.7.1408.
  • Thigpen J. T., Brady M. F., Homesley H. D. et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004 ; 22 (19): 3902-3908. Doi: 10.1200/ JCO.2004.02.088.
  • Fleming G.F., Brunetto V.L., Cella D. et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004 ; 22 (11): 2159-2166. Doi: 10.1200/JCO.2004.07.184.
  • Miller D. S., Filiaci V.L., Mannel R. S. et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology / GOG0209). J Clin Oncol 2020 ; 38 (33): 3841-3850. Doi: 10.1200/jc0.20.01076.
  • Miller D., Filiaci V., Fleming G. et al. Late-breaking abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012 ; 125 (3): Р. 771. Doi: 10.1016/j.ygyno.2012.03.034.
  • Нечушкина В. М., Коломиец Л. А., Кравец О. А., Морхов К. Ю., Новикова Е. Г., Новикова О. В., Тюляндина А. С. и др. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2022 (том 12). 260-275. Doi: 10.18027/2224-5057-2022-12-3s2-260-275.
  • National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology (NCCN Guidelines®) — Uterine Neoplasms. Version 1.2023 — December 22, 2022. Available at: https://www.nccn.org/professionals/physician_gls/ pdf/uterine.pdf.
  • Lorusso D., Ferrandina G., Colombo N. et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. J Clin Oncol. 2015 May ; 33 (15 suppl): 5502. Doi: 10.1200/jco.2015.33.15_suppl. 5502.
  • Aghajanian C., Filiaci V.L., Dizon D. S. et al. A randomized phase II study of paclitaxel / carboplatin/ bevacizumab, paclitaxel / carboplatin / temsirolimus and ixabepilone/ carboplatin / bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol 2015 ; 33 (suppl): Abstract 5500.
  • Fader A.N., Roque D.M., Siegel E. et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-pa-clitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2 / neu. J Clin Oncol 2018 ; 36 (20): 2044-51. Doi: 10.1200/jœ.2017.76.5966.
  • Lincoln S., Blessing J.A., Lee R.B. et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2003 ; 88 (3): 277-281. Doi: 10.1016/S0090-8258(02)00068-9.
  • Homesley H.D., Meltzer N. P., Nieves L. et al. A phase II trial of weekly 1-hour paclitaxel as second- line therapy for endometrial and cervical cancer// Int.J. Clin. Oncol .- 2008 .- 13 (1) .- P. 62-65. Doi: 10.1007/s10147-007-0731-5.
  • Garcia A.A., Blessing J.A., Nolte S. et al. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group. Gynecol Oncol. 2008 ; 111 (1): 22-26. Doi: 10.1016/j.ygyno.2008.06.013.
  • Tait D. L., Blessing J. A., Hoffman J. S. et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study.// Gynecol. Oncol .- 2011 .- 121 (1) .- P. 118-121. Doi: 10.1016/j.ygyno.2010.11.027.
  • Fracasso P. M., Blessing J.A., Molpus K. L. et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2006 ; 103 (2): 523-526. https://doi.org/10.1016/j. ygyno.2006.03.043.
  • Makker V., Hensley M.L., Zhou Q. et al. Treatment of Advanced or Recurrent Endometrial Carcinoma with Doxorubicin in Patients Progressing After Paclitaxel / Carboplatin: Memorial Sloan-Kettering Cancer Center Experience From 1995 to 2009. Int J Gynecol Cancer. 2013 ; 23 (5): 929-934. https://doi.org/10.1097/IGC.0b013e3182915c20.
  • Moreira E., Paulino E., Ingles Garces Ä. H. et al. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA). Med Oncol 2018 ; 35 (3): 20. Doi: 10.1007/s12032-018-1086-7.
  • Muggia F. M., Blessing J.A., Sorosky J. et al. Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study// J Clin Oncol. 2002 ; 20 (9): 2360-2364. Doi: 10.1200/jCO.2002.08.171.
  • Sutton G.P., Blessing J.A., Homesley H.D. et al. Phase II study of ifosfamide and mesna in refractory ade-nocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 1994 ; 73 (5): 1453-1455. Doi: 10.1002/1097-0142(19940301)73:5<1453::aid-cncr2820730521-3.0.co;2-x.
  • Rose P. G., Blessing J.A., Lewandowski G. S. et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study// Gynecol. Oncol .- 1996 .- 63 (1) .- P. 101-104. Doi: 10.1006/gyno.1996.0286.
  • Miller D. S., Blessing J.A., Lentz S. S. et al. A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study// Gynecol Oncol. 2002 ; 87 (3): 247-251. https://doi.org/10.1006/gyno.2002.6804.
  • Miller D. S., Blessing J. A., Drake R. D. et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gy-necol Oncol. 2009 ; 115 (3): 443-6. Doi: 10.1016/j.ygyno.2009.09.004.
  • Dizon D.S., Blessing J.A., McMeekin D. S. et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P// J. Clin. Oncol .- 2009 .- 27 (19) .- P. 3104-3108. Doi: 10.1200/JC0.2008.20.6995.
  • Markman M., Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 2004 ; 92 (1): 180-2. Doi: 10.1016/j.ygyno.2003.10.019.
  • Moore K.N., Tian C., McMeekin S. et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? Cancer 2010 ; 116 (23): 5407-14. Doi: 10.1002/cncr.25480.
  • Nagao S., Nishio S., Michimae H. et al. Applicability of the concept of «platinum sensitivity» to recurrent endometrial cancer: The SGSG-012/ G0TIC-004/ Intergroup study. Gynecol Oncol. 2013 Dec ; 131 (3): 567-73. Doi: 10.1016/j. ygyno.2013.09.021.
  • Slomovitz B. M., Jiang Y., Yates M. S. et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015 ; 33 (8): 930-936. Doi: 10.1200/jœ.2014.58.3401.
  • Coleman R.L., Sill M.W., Lankes H.A. et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2012 ; 127 (3): 538-543. Doi: 10.1016/j.ygyno.2012.08.020.
  • Makker V., Filiaci V. L., Chen L. M. et al. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/ Gynecologic Oncology Group Study 0229N. Gynecol Oncol. 2015 ; 138 (1): 24-9. Doi: 10.1016/j.ygyno.2015.04.006.
  • Aghajanian C., Sill M.W., Darcy K.M. et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 2011 ; 29 (16): 2259-2265. Doi: 10.1200/jœ.2010.32.6397.
  • Castonguay V., Lheureux S., Welch S. et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014 ; 134 (2): 274-280. Doi: 10.1016/j.ygyno.2014.05.016.
  • Nimeiri H. S., Oza A. M., Morgan R.J. et al. A phase II study of sorafenib in advanced uterine carcinoma/ carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010 ; 117 (1): 37-40. Doi: 10.1016/j.ygyno.2010.01.013.
  • Powell M.A., Sill M. W., Goodfellow P.J. et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRGOncology/ Gynecologic Oncology Group Study. Gynecol Oncol 2014 ; 135 (1): 38-43. Doi: 10.1016/j. ygyno.2014.07.083.
  • Dizon D. S, Sill M.W., Schilder J. M. et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology / Gynecologic Oncology Group Study. Gynecol Oncol 2014 ; 135 (3): 441-445. Doi: 10.1016/j.ygyno.2014.10.001.
  • Bender D., Sill M. W., Lankes H. A. et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study. Gynecol Oncol 2015 ; 138 (3): 507-512. Doi: 10.1016/j.ygyno.2015.07.018.
  • Moore K.N., Sill M.W., Tenney M.E. et al. A phase II trial of trebananib (AMG 386 ; IND#111071), a selective an-giopoietin 1/ 2 neutralizing peptibody, in patients with persistent / recurrent carcinoma of the endometrium: An NRG / Gynecologic Oncology Group trial. Gynecol Oncol 2015 ; 138 (3): 513-518. Doi: 10.1016/j.ygyno.2015.07.006.
  • Leslie K.K., Sill M.W., Fischer E. et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2013 ; 129 (3): 486-494. Doi: 10.1016/j. ygyno.2013.02.019.
  • Oza A. M., Eisenhauer E.A., Elit L. et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008 ; 26 (26): 4319-4325. Doi: 10.1200/jœ.2007.15.8808.
  • Slomovitz B. M., Chelariu-Raicu A., Schmeler K. M. et al. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer. 2020 ; 30 (11): 1733-1737. Doi: 10.1136/ijgc-2020-001859.
  • Fleming G.F., Sill M.W., Darcy K.M. et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2010 ; 116 (1): 15-20. Doi: 10.1016/j.ygyno.2009.09.025.
  • Leslie K. K., Sill M.W., Lankes H.A. et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012 ; 127 (2): 345-350. Doi: 10.1016/j.ygyno.2012.07.127.
  • Slomovitz B. M., Lu K. H., Johnston T. et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010 ; 116 (23): 5415-5419. Doi: 10.1002/cncr.25515.
  • Ray-Coquard I., Favier L., Weber B. et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer 2013 ; 108 (9): 1771-1777. Doi: 10.1038/bjc.2013.183.
  • Oza A. M., Elit L., Tsao M. S. et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol 2011 ; 29 (24): 3278-3285. Doi: 10.1200/jc0.2010.34.1578.
  • Fleming G. F., Filiaci V. L., Marzullo B. et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2014 ; 132 (3): 585-592. Doi: 10.1016/j.ygyno.2014.01.015.
  • Colombo N., McMeekin D. S., Schwartz P. E. et al. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial. Br J Cancer 2013 ; 108 (5): 1021-1026. Doi: 10.1038/bjc.2013.59.
  • Oza A. M., Pignata S., Poveda A. et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol 2015 ; 33 (31): 3576-3582. Doi: 10.1200/jœ.2014.58.8871.
  • Alvarez E.A., Brady W. E., Walker J. L. et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2013 ; 129 (1): 22-27. Doi: 10.1016/j.ygyno.2012.12.022.
  • Cancer Genome Atlas Research Network, Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A. G., Pashtan I., Shen R., Benz C. C., Yau C., Laird P.W., Ding L., Zhang W., Mills G. B., Kucherlapati R., Mardis E.R., Levine D.A. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May ; 497 (7447): 67-73. Doi: 10.1038/nature12113.
  • Talhouk A., McConechy M. K., Leung S. et al. A clinically applicable molecular-based classification for endometrial cancers// Br J Cancer. 2015 ; 113 (2): 299-310. Doi: 10.1038/bjc.2015.190.
  • Talhouk A., McConechy M. K., Leung S. et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer // Cancer .- 2017 .- №123 .- P. 802-813.
  • Talhouk A., Hoang L.N., McConechy M. K. et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment // Gynecol. Oncol .- 2016 .- №143 (1) .- P. 46-53. Doi: 10.1016/j.ygyno.2016.07.090.
  • Kandoth C., Schultz N., Cherniack A.D. et al. Integrated genomic characterization of endometrial carcinoma// Nature .- 2013 .- 497 (7447) .- P. 67-73. Doi: 10.1038/nature12113.
  • Bansal N., Yendluri V., Wenham R. M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies// Cancer Control .- 2009 .- №16 (1) .- P. 8-13. Doi: 10.1177/107327480901600102.
  • Chernukha G. E., Dumanovskaya M. R., Burmenskaya O. V. et al. Expression of apoptosis-regulatory genes in different endometrial hyperplasia types and endometrioid carcinoma// Obstetrics and Gynecology .- 2013 .- № 1 .- P. 63-69.
  • Lorenzi M., Amonkar M., Zhang J. et al. Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review. J Oncol. 2020 ; 1-17. https:// doi.org/10.1155/2020/1807929.
  • Marabelle A., Fakih M., Lopez J. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020 ; 21 (10): 1353-65. Doi: 10.1016/S1470-2045(20)30445-9.
  • Le D. T., Uram J. N., Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015 ; 372 (26): 2509-20. Doi: 10.1056/NEJMoa1500596.
  • Marabelle A., Le D. T., Ascierto P.A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability / mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020 ; 38 (1): 1-10. https://doi.org/10.1200/jCO.19.02105.
  • Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ, Merck Sharp & Dohme, 2018.
  • Arora E., Masab M., Mittar P. et al. Role of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Cureus 2018 ; 10: e2521.
  • Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the anti-PD- 1 monoclonal antibody dostar-limab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol. 2021 ; 17 (29): 3781-3785. https://doi.org/10.2217/fon-2021-0598.
  • Antill Y., Kok P. S., Stockler M. R. et al. Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). Ann Oncol 2019 ; 30 (Suppl 9): P. ix192. https://doi.org/10.1093/annonc/mdz446.011.
  • Diaz L.A., Marabelle A., Delord J.P. et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncology. 2017 ; 35 (15): 3071. Doi: 10.1200/jœ.2017.35.15_suppl.3071.
  • O'Malley D. M., Bariani G. M., Cassier P.A. et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022 ; 40 (7): 752-61. Doi: 10.1200/ jCO.21.01874.
  • Hasegawa K., Tamura K., Katsumata N. et al. Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers. J Clin Oncol 2018 ; 36 (Suppl 15): 5594. Doi: 10.1200/jco.2018.36.15_ suppl.5594.
  • Konstantinopoulos P. A., Luo W., Liu J. F. et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent / persistent endometrial cancer. J Clin Oncol 2019 ; 37 (30): 2786-94. Doi: 10.1200/ JCO. 19.01021.
  • Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the antiprogrammed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a non-randomized phase 1 clinical trial. JAMA Oncol 2020 ; 6 (11): 1766-1772. Doi: 10.1001/jamaoncol.2020.4515.
  • Antill Y. C., Kok P .- S., Robledo K. et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). J Clin Oncol 2019 ; 37 (15 Sup-pl): abstr 5501. Doi: 10.1200/jœ.2019.37.15_suppl.5501.
  • Ott P. A., Bang Y.J., Berton-Rigaud D. et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study J Clin Oncol. 2017 Aug 1 ; 35 (22): 2535-2541. Doi: 10.1200/jœ.2017.72.5952.
  • Binnewies M., Roberts E.W., Kersten K. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018 ; 24 (5): 541-50. Doi: 10.1038/s41591-018-0014-x.
  • Hong D. S., Kurzrock R., Wheler J.J. et al. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res 2015 ; 21: 4801-10. Doi: 10.1158/1078-0432.CCR-14-3063.
  • Vergote I., Powell M.A., Teneriello M. G. et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020 ; 156 (3): 575-582. Doi: 10.1016/j.ygyno.2019.12.039.
  • Vergote I., Teneriello M., Powell M. A. et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol 2013 ; 31 (15 Suppl): abstr 5520.
  • Mittica G., Ghisoni E., Giannone G., et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity// Oncotarget .- 2017 .- 8 (52) .- P. 90532-90544. Doi: 10.18632/ oncotarget. 20042.
  • Lenvima (lenvatinib) [package insert]. Woodcliff Lake, Nj, Eisai, 2019.
  • Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and betond. World J Gastroenterol 2019 ; 25 (7): 789-807. https://dx.doi.org/10.3748/wjg.v25.i7.789.
  • Vanderstraeten A., Tuyaerts S., Amant F. The immune system in the normal endometrium and implications for endometrial cancer development// J. Reprod. Immunol .- 2015 .- 109 .- P. 7-16. Doi: 10.1016/j.jri.2014.12.006.
  • Herzog T.J., Arguello D., Reddy S.K., et al. PD-1, PD-L1 expression in 1599 gynecological cancers: implications for immunotherapy// Gynecol. Oncol .- 2015 .- 137 (suppl 1) .- P. 204-205.
  • Brahmer J. R., Tykodi S. S., Chow L. Q. M. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer // N. Engl.J. Med .- 2012 .- 366 (26) .- P. 2455-2465. Doi: 10.1056/NEjMoa1200694.
  • Ishida Y., Agata Y., Shibahara K. et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death // EMBO J .- 1992 .- 11 (11) .- P. 3887-3895. Doi: 10.1002/j.1460-2075.1992. tb05481.x.
  • Carreno B. M., Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses // Annu. Rev. Immunol .- 2002 .- 20 .- P. 29-53. Doi: 10.1146/annurev.immunol.20.091101.091806.
  • Latchman Y., Wood C. R., Chernova T. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation// Nat. Immunol .- 2001 .- 2 (3) .- P. 261-268. Doi: 10.1038/85330.
  • Francisco L.M., Sage P. T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity// Immunol. Rev .- 2010 .- 236 .- P. 219-242. Doi: 10.1111/j.1600-065X.2010.00923.x.
  • Freeman G.J., Long A.J., Iwai Y. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation// J. Exp. Med .- 2000 .- 192 (7) .- P. 1027-1034. Doi: 10.1084/ jem.192.7.1027.
  • Makker V., Taylor M. H., Aghajanian C. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020 ; 38 (26): 2981-2992. Doi: 10.1200/jœ.19.02627.
  • Arora S., Balasubramaniam S., Zhang W. et al. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. Clin Cancer Res. 2020 ; 26 (19): 5062-5067. Doi: 10.1158/1078-0432.CCR-19-3979.
  • U. S. Food and Drug Administration. Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US. https://www.fda.gov/drugs/resources-information-approved-drugs/simultaneous-review-decisions-pem-brolizumabplus-lenvatinib-australia-canada-and-us. Accessed March 18, 2020.
  • Makker V., Colombo N., Herraez A. C., et al. A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. Gynecol Oncol. 2021 ; 162 (suppl 1): S4 https://doi.org/10.1016/S0090-8258(21)00657-0.
  • Colombo N., Lorusso D., Casado A., et al. Outcomes by histology and prior therapy with lenvatinib plus pembroli-zumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309 / KEYNOTE-775). Presented at: European Society for Medical Oncology (ESMO) Congress 2021 ; September 16-21, 2021. Abstract 726MO.
  • Hasegawa K., Nagao S., Yasuda M. et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. Int J Gynecol Cancer. 2014 ; 24 (3 Suppl.): S90 — S95. https:// doi.org/10.1097/IGC. 0000000000000297.
  • Sagae S., Susumu N., Viswanathan A. N. et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma. Int J Gynecol Cancer. 2014 ; 24 (3 Suppl.): S83 — S89. https://doi.org/10.1097/IGC. 0000000000000264.
  • Lee C .- H., Shah A.Y., Hsieh J.J., Rao A., Pinto A., Bilen M.A. et al. Phase II trial of lenvatinib (LEN) plus pem-brolizumab (PEMBRO) for disease progression after PD-1/ PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol. 2020 ; 38 (15 Suppl.): abstr 5008. https://doi.org/10.1200/JCO. 2020.38.15_suppl. 5008.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp